Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fungibax +
- Development stage
- Unknown
- Lead developer
- Medicox Lifescience
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Fungibax +** is a topical fixed-dose cream marketed by Medicox Lifescience containing clobetasol propionate, miconazole nitrate, and neomycin sulfate. It combines a potent topical glucocorticoid for inflammatory dermatoses, an imidazole antifungal that disrupts fungal ergosterol biosynthesis, and an aminoglycoside antibacterial agent. The product is marketed for fungal and bacterial skin infections and steroid-responsive skin conditions such as dermatitis and eczema when secondary microbial infection is present or suspected.
- Brand names
- Fungibax +
- Other names
- Fungibax
02
Targets
Bacterial RibosomeCYP51A1 (Sterol 14α-demethylase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Fungibax +.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fungibax +.